L ater this month, the Management Board of the European Medicines Agency (EMA) will meet to discuss the agency's finalized policy on the publication of, and access to, clinical trial data. As a response to this policy and similar transparency initiatives at the US Food and Drug Administration (FDA), industry trade associations have put forward their own principles for voluntarily making human testing data available to "qualified researchers. " Although these moves to greater transparency are a positive development, they are being played out against a backdrop in which company secrecy-specifically confidential business information (CBI)-is on the rise. According to the Feature on p. 528, the use of CBI is increasing not only for drug products, but also for biotech seed products. As society as a whole moves toward greater openness, industry must be careful to balance its imperative to protect CBI with the calls from researchers, physicians and patients for greater transparency.
CBI is an umbrella term for what are known legally as 'trade secrets' . It refers to commercially valuable information that is not widely known to other businesses and thus gives its owner a competitive advantage. A trade secret can refer to any information (product composition/formulation, device, method, technique or process) that has value as long as it remains hidden from competitors. A classic example is the formula of Coca-Cola.
The biotech industry has traditionally used a mix of intellectual property (IP) strategies for its platforms and products, including the filing of patents, the publication of scientific papers and the use of trade secrets. As the industry has matured, however-and larger, more profitable biotech firms have come to the fore-the tendency towards trade secrets has increased. In other words, biotech companies are beginning to resemble their larger, more secretive, pharmaceutical brethren.
According to data gathered by Nature Biotechnology, plant biotech has witnessed a tenfold increase in the use of CBI since 1993. Indeed, CBI is invoked with increasing regularity, despite the fact that regulatory registrations have been on the decline since 2002. In the biopharmaceutical sector, increasing tracts of regulatory documents describing the constructs and sequences of biologic drugs are redacted as CBI, making it difficult to tell exactly the composition of newly approved products.
One reason why trade secrets are becoming so pervasive is that legal definitions of what is and what is not CBI are so vague. This gives companies leeway to invoke CBI in all manner of contexts, often with little justification. At the same time, regulators' default attitude is to redact any of the documentation associated with a product registration that could be construed as CBI because of the substantial fines and even jail time associated with disclosure of trade secrets.
Another explanation for the rise of CBI is the increasingly competitive business environment; today, manufacturers must contend not only with other brands seeking to take their market share, but also with the prospect of biosimilar competitors. In this context, it is very much in the interest of innovator companies to place off limits an increasing amount
Best-kept secrets
Industry needs to fully embrace efforts by regulators to release clinical trial data on approved products, despite lingering concerns over the public release of confidential business information. It is simply the right thing to do.
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